The CAR-T cell therapy market is estimated to be worth USD 14 billion in 2030, predicts Roots Analysis
CAR-T Cell Therapies Market (3rdEdition) by Target Indications

Given their abilityto selectively direct a cell mediated immune response against cancer cells and,thereby, offer prolonged periods of disease remission, several CAR-T celltherapies are expected to achieve blockbuster status


Roots Analysis is pleased toannounce the publication of its recent study, titled, “CAR-T Cell Therapies Market (3rdEdition) by Target Indications (NHL, Multiple Myeloma, Chronic LymphocyticLeukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle CellLymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA,CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America,Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of theWorld) – Industry Trends and Global Forecasts, 2021-2030


The features an extensive study of the currentmarket landscape and the future potential of CAR-T cell therapies. The reporthighlights the efforts of both industry players and academic organizations inthis rapidly evolving segment of the biopharmaceutical industry. Amongst otherelements, the report features the following:

§ A detailed assessmentof the current market landscape of drug developers engaged in the developmentof CAR-T cell therapies.

§ Detailed profiles ofmarketed and mid-to late stage clinical products (shortlisted on the basisof the stage of development).

§ An analysis of theCAR constructs of clinical-stage CAR-T therapies based on the generation ofCAR-T therapy.

§ An analysishighlighting the key opinion leaders (KOLs) in this domain. It features a 2×2matrix assessing the relative experience of KOLs shortlisted based on theircontributions (in terms of involvement in various clinical studies) tothis field.

§ An analysis of thevarious CAR-T cell therapy focused clinical trials registered across the world,between 2009 and 2019.

§ An overview of thevarious focus therapeutic areas of therapy developers, including an assessmentof the opportunity (in terms of revenue generation potential from therapysales) across oncological and non-oncological disease indications.

§  A detailed discussionon innovative technology platforms that are being used for the development of CAR-Tcell therapies.

§ An analysis of the partnerships that have been establishedin the recent past.

§ An analysis of the investments that have been made intocompanies that have proprietary CAR-T cell based products / technologies.

§ A case study on other T-cell based therapies, apart fromCAR-Ts, including a detailed analysis of approved / pipeline products.

§ A case study on manufacturing cell therapy products,highlighting the key challenges, and a detailed list of contract serviceproviders and in-house manufacturers involved in this space.

§ An elaborate discussion on various factors that form thebasis for the pricing of cell-based therapies.

§ An analysis of the prevalent and emerging trends in thisdomain, as represented on the social media platform, Twitter.

§ A review of the key promotional strategies that have beenadopted by the developers of the marketed CAR-Tcell therapies.

§  A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)

  • Type of target disease Indication
    • Non-Hodgkin’s lymphoma
    • Multiple myeloma
    • Melanoma
    • Chronic lymphocytic leukemia

§  Acutelymphoblastic leukemia

§  Follicularlymphoma

§ Mantle cell lymphoma

  • Hepatocellular carcinoma

§ Colorectal cancer


§  Typeof Target Antigens

  • CD19
  • BCMA
  • CD19, CD22
  • GPC3
  • EGFR


§  KeyGeographical Regions 

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and North Africa
  • Rest of the World 


§  Transcripts ofinterviews held with the following senior level representatives of stakeholdercompanies

  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)


Key companies coveredin the report

  • Autolus
  • bluebird bio
  • CARsgen Therapeutics

§ Celgene (A BristolMyers Squibb Company)

  • Cellectis
  • Cellular Biomedicine Group
  • Innovative Cellular Therapeutics
  • Iovance Biotherapeutics
  • Kite Pharma (A Gilead Sciences Company)
  • Kuur Therapeutics
  • Lion TCR
  • Noile-Immune Biotech
  • Novartis
  • Shanghai GeneChem
  • Sinobioway Cell Therapy
  • Takara Bio
  • Ziopharm Oncology


Formore information please click on the following link:


Other Recent Offerings

1.  Global T-Cell (CAR-T,TCR, and TIL) Therapy Market (5th Edition), 2021 – 2030


2. mRNA Therapeutics andVaccines Market, 2020-2030

3. Gene Therapy Market(4th Edition): Industry Trends and Global Forecasts, 2020-2030

4. Oncolytic Virus TherapyMarket: Pipeline Review, Developer Landscape and Competitive Insights,2020-2030

About Roots Analysis

Roots Analysis is oneof the fastest growing market research companies, sharing fresh and independentperspectives in the bio-pharmaceutical industry. The in-depth research,analysis and insights are driven by an experienced leadership team which hasgained many years of significant experience in this sector. If you’d like helpwith your growing business needs, get in touch at


Contact Information

Roots AnalysisPrivate Limited

Gaurav Chaudhary

+1 (415) 800 3415